Analysis on the Marketing Trend and Approval Lag of Imported Orphan Drugs from 2010 to 2021 in China

作者全名："Peng, Feifei; Zheng, Hang"

作者地址："[Peng, Feifei; Zheng, Hang] Chongqing Med Univ, Sch Pharmaceut Sci, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China"

通信作者："Zheng, H (通讯作者)，Chongqing Med Univ, Sch Pharmaceut Sci, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China."

来源：THERAPEUTIC INNOVATION & REGULATORY SCIENCE

ESI学科分类：PHARMACOLOGY & TOXICOLOGY

WOS号：WOS:001062521700001

JCR分区：Q3

影响因子：2

年份：2023

卷号：　

期号：　

开始页：　

结束页：　

文献类型：Article; Early Access

关键词：Orphan drugs; Approval lag; China; Marketing trend; Rare disease

摘要："BackgroundIn order to meet the unmet needs of rare disease patients in China, importing orphan drugs is an important way. The objectives of this study were to investigate the marketing trend of orphan drugs approved by the US Food and Drug Administration (FDA) and imported by China, to examine the orphan drug lag between China and the United States.MethodsThis study analyzes the orphan drugs approved by FDA and imported by China from January 2010 to December 2021. The approval lag for orphan drugs between China and the US was calculated and analyzed by approval time. Factors potentially affecting the approval lag, such as target disease, ATC classification, formulation, corporation name, drug type, and whether the indications belong to the first batch of rare diseases catalogue were investigated.ResultsThe number of FDA-approved orphan drugs imported by China is increasing year by year, and the approval lag of these drugs is gradually decreasing, especially in the classification of Non-L, Injections, Non-United States, and biological product. Compared with 2010-2015, the approval lag of total drugs in the study was significantly improved in 2016-2021 (1977 days) compared with 2010-2015 (3928 days).ConclusionChina's groundbreaking regulatory reforms of drugs since 2015 had made significant progress in reducing orphan drug lags, but there is still considerable room for progress. We should more actively promote the approval of rare disease drugs in China, establish a better approval mechanism, and enable Chinese patients with rare diseases to receive drug treatment in a timely manner."

基金机构：　

基金资助正文：